Health Economic Outcomes/Comparative Effectiveness Research/Health Technology Assessment Track at DIA's 49th Annual Meeting

TRACK 13: HEALTH ECONOMICS AND OUTCOMES (HEO)/COMPARATIVE EFFECTIVENESS RESEARCH (CER)/HEALTH TECHNOLOGY ASSESSMENT (HTA) Learning Objectives:  Describe current issues in measuring and communicating the medical need, health impact, and economic value associated with medical products How can clinical trial design impact reimbursement potential?

How are comparative effectiveness research and HTA applicable to the biopharmaceutical industry?

What are the pharma, safety, and patient perspectives on big data methodology?

2012 US Payer Landscape survey looks at CER and EBM use in coverage decision making.

What are benefits and outcomes of collaborations between payers and pharmaceutical companies?

How can we utilize EMRs as an  innovative methodology for evaluating Therapeutic Effectiveness?

What are different ways for incorporating patient-centered approaches in model development?

What are pros/cons of using observational methods to support comparative effectiveness research?

How can information sharing  be facilitated across Sponsors, Regulatory and HTA Agencies?

How do Public and Private Payers translate CER into Medical Payment Policy?